Emergent BioSolutions Inc. Q1 2026 Earnings Recap

EBS Q1 2026 May 4, 2026

Get alerts when EBS reports next quarter

Emergent shares rose 3.8% after the quarter, reflecting market approval of better-than-expected revenue and adjusted EBITDA results, driven by solid demand in medical countermeasures and continued naloxone leadership.

Earnings Per Share Beat

$0.21 vs $-0.25 est.

+184.0% surprise

Revenue Beat

156100000 vs 145000000 est.

+7.7% surprise

Market Reaction

1-Day +5.97%

5-Day +11.24%

See EBS alongside your other holdings

Add to your portfolio — free

Key Takeaways

Q1 revenue of $156 million exceeded the high end of guidance and internal expectations.
Adjusted EBITDA reached $36 million, with a 23% margin, driven by operational efficiency and cost controls.
Medical Countermeasures (MCM) segment performed well, supported by global demand and a $140 million multiproduct agreement with Canada.
Naloxone franchise maintains market share leadership; recent product launches (carrying case, multipack) showing early positive traction.
Continued balance sheet improvement with $110 million debt repayment in 2025 and ongoing share repurchases totaling $34 million since 2025 start.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit EBS on AllInvestView.